Akero Therapeutics surges on mid-stage data from liver disease trial

Akero Therapeutics

27/01/2025 12:10

** Shares of drug developer Akero Therapeutics  AKRO.O  rise
91.5% to $50.14 premarket 
    ** AKRO reports positive preliminary results from mid-stage
trial testing its lead experimental drug to treat liver scarring
caused by metabolic dysfunction-associated steatohepatitis
(MASH) - a type of fatty liver disease 
    ** Co says 39% of patients treated with drug efruxifermin
showed reversal of liver scarring with no worsening of MASH,
compared to 15% for placebo 
    ** Adds it will continue to evaluate efruxifermin in ongoing
late-stage study 
    ** AKRO says the drug was generally well-tolerated with no
related deaths, adds there was one death in the placebo arm due
to pneumonia
    ** Stock rose 19.1% in 2024 

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))